Previous 10 | Next 10 |
VANCOUVER, British Columbia, May 13, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of canna...
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development ...
VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical developmen...
InMed Pharmaceuticals (INM) has filed Clinical Trial Applications (CTAs) in Austria, Israel and Serbia as part of a Phase 2 study of INM-755 (cannabinol) cream in Epidermolysis Bullosa ((EB)).Additional CTAs for 755-201-EB (the ‘201 study) will be submitted to regulatory authorities in...
Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream Additional submissions slated for France, Germany, Greece, and Italy over the next several days and weeks. Anticipated study on track to begin in 3Q 2021 VANCOUVER, British C...
VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical developm...
VANCOUVER, British Columbia, April 26, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development ...
InMed Pharmaceuticals went public last November. The company is developing the application of rare cannabinoids to treat glaucoma and skin disease. They have a method for synthesizing bio-identical cannabinoids from enzymes. The company is funded by direct offerings and operat...
VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unme...
InMed Announces Closing of US$4.5 Million Private Placement PR Newswire VANCOUVER, BC , Feb. 16 , 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medicat...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...